StockVS

NASDAQ · Biotechnology · USD

XORTX Therapeutics Inc. (XRTX) Stock Analysis

XORTX Therapeutics Inc. (XRTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

XRTX

$0.93

−$0.03 (−2.66%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XRTX with… →

XRTX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.97
Previous Close
$0.96
Day's Range
0.90–1.05
52-Week Range
0.90–3.89
Volume
72.29K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.58
Valuation
Market Cap
$1.69M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
1.16
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.61
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$2.66M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.82M
1-Year Return
−74.34%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
720.24K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, XRTX closed at $0.93, −74.34% over 1 year.

XORTX Therapeutics Inc. (XRTX) has a market capitalization of $1.69M.

In fiscal 2025, XRTX reported revenue of $0.00.

XRTX Stock Return by Calendar Year

XORTX Therapeutics Inc. (XRTX) return since Sep 2021: what $10,000 became

1 year
$10,000 $2,566
−74.34%
5 years
$10,000 $8
−99.92%
Since Sep 2021
$10,000 $5
−99.95%

If you had invested $10,000 in XORTX Therapeutics Inc. (XRTX) at the close on September 23, 2021, the earliest close on record here, it would have been worth $5 at the close on October 21, 2026: −99.95% in total, −78.01% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−66.90%
2025−50.27%
2024−51.08%
2023−96.47%
2022−60.59%
2021 (partial year)−59.11%

As of October 21, 2026.

XRTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$2.66M—
2024$0.00−$3.31M—
2023$0.00−$2.16M—
2022$0.00−$7.72M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$3.26M−$2.66M—
2024$0.00—−$4.12M−$3.31M—
2023$0.00—−$6.05M−$2.16M—
2022$0.00—−$10.29M−$7.72M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

XORTX Therapeutics Inc. (XRTX) is capitalised at $1.69M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for XRTX is $0.93, dated October 21, 2026. That is −$0.03 (−2.66%) against the previous close. Over the past 52 weeks the price has ranged from $0.90 to $3.89. The latest close sits 3.32% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $2.66M. Earnings per share on a trailing basis come to −2.61.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 1.16.

Beta against the wider market is reported at 0.58. Daily returns over the trailing 5 years annualize to a volatility of 142.61%. Over the trailing twelve months the total return is −74.34%. Across 5 years the annualized return works out at −76.11%.

Growth & Income

The record shows no dividend for XRTX.

2026 is still running; the total return is −66.90% year to date. Across the complete calendar years on file, 2025 returned −50.27% and 2023 returned −96.47%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

XORTX Therapeutics Inc. (XRTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
XORTX Therapeutics Inc. XRTX $1.69M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. XORTX Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

View all Biotechnology stocks →

Popular Healthcare Stocks

View all Healthcare stocks →

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Visit website →